Evidence map›Paper›PMID 35110355›Full record

ArticleJournal for immunotherapy of cancer2022

Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes.

Parin Shah, Marie-Andrée Forget, Meredith L Frank, Peixin Jiang, Donastas Sakellariou-Thompson, Lorenzo Federico, Roohussaba Khairullah, Chantal Alexia Neutzler, Ignacio Wistuba, Chi-Wan B Chow and 18 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  8. Review
  9. Article
  10. Extracellular vesicle surface display enhances the therapeutic efficacy and safety profile of cancer immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 1 institution in 1 country.

Parin Shah *Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Marie-Andrée Forget *Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Meredith L Frank *Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-3658-0057
Peixin JiangThoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Donastas Sakellariou-ThompsonBiologics Development, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lorenzo FedericoMelanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Roohussaba KhairullahThoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Chantal Alexia NeutzlerBiologics Development, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ignacio WistubaThoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Chi-Wan B ChowDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yan LongDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Junya FujimotoDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Shiaw-Yih LinDepartment of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Anirban MaitraDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Marcelo V NegraoThoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-8938-6699
Kyle Gregory MitchellThoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-4386-3258
Annikka WeissferdtDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ara A VaporciyanThoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tina CasconeThoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jack A RothThoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jianjun ZhangThoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-7872-3477
Boris SepesiThoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Don L GibbonsThoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
John V HeymachThoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cara L HaymakerDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Daniel J McGrailDepartment of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org.
Alexandre ReubenThoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org.ORCID 0000-0003-4510-0382
Chantale BernatchezMelanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org.ORCID 0000-0001-5926-3460
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4M
Determining the Immunological Consequences of DNA Replication Stress Response Defects in Renal Cells Carcinoma to Improve Immunotherapy OutcomesK99CA240689 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MCGRAIL, DANIEL JAMES · 2019 to 2020
$207k
NCI NIH HHS K99 CA240689NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907
6 · The paper itself

Abstract

backgroundAdoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) yielded clinical benefit in patients with checkpoint blockade immunotherapy-refractory non-small cell lung cancer (NSCLC) prompting a renewed interest in TIL-ACT. This preclinical study explores the feasibility of producing a NSCLC TIL product with sufficient numbers and enhanced attributes using an improved culture method.

methodsTIL from resected NSCLC tumors were initially cultured using (1) the traditional method using interleukin (IL)-2 alone in 24-well plates (TIL 1.0) or (2) IL-2 in combination with agonistic antibodies against CD3 and 4-1BB (Urelumab) in a G-Rex flask (TIL 3.0). TIL subsequently underwent a rapid expansion protocol (REP) with anti-CD3. Before and after the REP, expanded TIL were phenotyped and the complementarity-determining region 3 β variable region of the T-cell receptor (TCR) was sequenced to assess the T-cell repertoire.

resultsTIL 3.0 robustly expanded NSCLC TIL while enriching for CD8

conclusionsWe report the feasibility of robustly expanding a T-cell repertoire recapitulating the clonal hierarchy of the T cells in the NSCLC tumor, including a large number of putative tumor-specific TIL clones, using the TIL 3.0 methodology. If scaled up and employed as a sole expansion platform, the robustness and speed of TIL 3.0 may facilitate the testing of TIL-ACT approaches in NSCLC.

Indexed as

AgedAged, 80 and overCarcinoma, Non-Small-Cell LungCD3 ComplexFemaleHumansInterleukin-2Lung NeoplasmsLymphocytes, Tumor-InfiltratingMaleMiddle AgedTranslational Research, BiomedicalTumor Necrosis Factor Receptor Superfamily, Member 9CD3 ComplexIL2 protein, humanInterleukin-2TNFRSF9 protein, humanTumor Necrosis Factor Receptor Superfamily, Member 9adoptiveantigenimmunotherapylung neoplasmslymphocytesreceptorstranslational medical researchtumor-infiltrating

Identifiers

PMID35110355
PMCPMC8811607
OpenAlexW4210440082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.